Poster #250 A MULTI-CENTRE, RANDOMISED CONTROLLED TRIAL OF A GROUP PSYCHOLOGICAL INTERVENTION FOR PSYCHOSIS WITH COMORBID CANNABIS DEPENDENCE OVER THE EARLY COURSE OF ILLNESS

Madigan, Kevin; Lawlor, Elizabeth R.; Brennan, Daria; Turner, Niall; Kinsella, Anthony; O’Connor, John; Russell, Vincent; Waddington, John L.; O’Callaghan, Eadbhard

doi:10.1016/s0920-9964(12)71082-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four trials reported use of a retrospective use diary or calendar (Roffman et al, 1989;Sinha et al, 2003;Stephens et al, 1994Stephens et al, , 2000, and four trials reported use of a self-report instrument but did not provide additional details (Carpenter et al, 2009;Johnston et al, 2014;Levin et al, 2004;Tossmann et al, 2011). Two trials (Dennis et al, 2004;Madigan et al, 2013) used single-item measures from other scales, the Global Appraisal of Individual Needs (GAIN; Dennis et al, 2004), and the cannabis abuse subscale of the Addiction Severity Index (ASI;McLellan et al, 1992).…”

Section: Cannabis Use Measuresmentioning

confidence: 99%

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder

Lee

Schlienz

Peters

et al. 2019

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Cannabis use disorder (CUD) is prevalent and demand for treatment is increasing, yet few individuals engage in formal treatment and the efficacy of established interventions for CUD is modest. Existing clinical trials evaluating psychosocial and pharmacological treatments for CUD have incorporated a wide variety of measures for assessing cannabis use outcomes, including abstinence, self-reported frequency and quantity used, withdrawal, use/dependence severity, and other psychosocial outcomes. The heterogeneity of measures and outcomes has limited quantitative analyses of the comparative effectiveness of existing interventions. The purpose of this systematic review is to: 1) identify and characterize approaches for measuring cannabis use in existing CUD intervention trials, including abstinence, frequency and quantity of use, and 2) summarize measures used to assess treatment efficacy in other outcome domains (e.g., cannabis use severity, psychosocial functioning, cannabis withdrawal), and provide a platform for future research to evaluate which outcome measures are most likely to reflect treatment efficacy and clinically significant improvement in other outcome domains.

show abstract